Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Change In Payables And Accrued Expense : NT$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Change In Payables And Accrued Expense?

Great Novel Therapeutics Biotech & Medicals's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was NT$0.00 Mil. It means Great Novel Therapeutics Biotech & Medicals's Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Dec. 2023 .

Great Novel Therapeutics Biotech & Medicals's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was NT$0.00 Mil. It means Great Novel Therapeutics Biotech & Medicals's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

Great Novel Therapeutics Biotech & Medicals Change In Payables And Accrued Expense Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Change In Payables And Accrued Expense Chart

Great Novel Therapeutics Biotech & Medicals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial					-	-	-	-	-

Great Novel Therapeutics Biotech & Medicals Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.00 Mil.

Great Novel Therapeutics Biotech & Medicals Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503

Website

http://www.gntbm.com.tw

Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines